Alliance Wealth Advisors LLC UT Buys 3,166 Shares of Zoetis Inc. $ZTS

Key Points

• Alliance Wealth Advisors LLC UT increased its stake in Zoetis Inc. by 16.1%, owning 22,886 shares valued at approximately $3.77 million after acquiring additional shares in the first quarter.
• Several analysts have adjusted their price targets for Zoetis, with Leerink Partners lowering the target from $180 to $155, while Piper Sandler raised it from $210 to $215, reflecting the mixed sentiments towards the stock.
• Zoetis reported quarterly earnings of $1.76 EPS, exceeding estimates of $1.62, with revenue of $2.46 billion, representing a 4.2% increase compared to the previous year.

Alliance Wealth Advisors LLC UT grew its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 16.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 22,886 shares of the company's stock after buying an additional 3,166 shares during the period. Alliance Wealth Advisors LLC UT's holdings in Zoetis were worth $3,768,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Portside Wealth Group LLC increased its position in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company's stock worth $5,550,000 after purchasing an additional 6,672 shares during the last quarter. Tandem Investment Advisors Inc. increased its position in shares of Zoetis by 100.3% in the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company's stock worth $65,140,000 after purchasing an additional 198,089 shares during the last quarter. Flagship Harbor Advisors LLC increased its position in shares of Zoetis by 31.2% in the first quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company's stock worth $1,217,000 after purchasing an additional 1,760 shares during the last quarter. Horizon Financial Services LLC bought a new position in shares of Zoetis in the first quarter worth approximately $380,000. Finally, Sage Rhino Capital LLC increased its position in shares of Zoetis by 117.6% in the first quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company's stock worth $1,155,000 after purchasing an additional 3,791 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

NYSE ZTS traded down $1.83 on Monday, reaching $152.28. 2,158,515 shares of the company's stock traded hands, compared to its average volume of 3,678,922. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The stock has a 50-day simple moving average of $154.69 and a 200 day simple moving average of $158.90. The stock has a market cap of $67.49 billion, a PE ratio of 26.21, a P/E/G ratio of 2.47 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter last year, the business earned $1.56 earnings per share. The business's revenue was up 4.2% on a year-over-year basis. As a group, research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.3%. Zoetis's dividend payout ratio (DPR) is currently 34.42%.

Insider Activity

In other news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at approximately $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Wall Street Analyst Weigh In

ZTS has been the topic of several research analyst reports. Stifel Nicolaus cut shares of Zoetis from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Leerink Partners cut shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Leerink Partnrs cut shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. UBS Group reduced their price target on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research report on Wednesday, May 7th. Finally, Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of "Moderate Buy" and a consensus price target of $202.43.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.